Werner not good enough for Roche
Roche dumps another partnered asset.
BioNTech turns $800m into $1.5bn-plus
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
